CCST will commence dosing for the SIMBA study in early 2018 . This study is sponsored by Merck KGaA, Germany. This randomised, double blind single dose study is comparing the Pharmacokinteics, Pharmacodynamics, Safety, Tolerability and Immunogenicity of MSB 11456, US licensed Acterma and EU approved RoActerma in Healthy Adult Subjects. CCST aims to recruit 160 volunteers and complete the study in the first quarter of 2018. This study will be conducted at 2 study centres in NZ.